ADIL Adial Pharmaceuticals Inc
Price (delayed)
$0.656
Market cap
$4.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.72
Enterprise value
$562,405
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist,
Highlights
The company's EPS rose by 30% QoQ and by 24% YoY
Adial Pharmaceuticals's net income has plunged by 158% YoY
Adial Pharmaceuticals's quick ratio has decreased by 39% QoQ and by 11% YoY
Key stats
What are the main financial stats of ADIL
Market
Valuations
Earnings
Shares outstanding
6.57M
Market cap
$4.31M
Enterprise value
$562,405
Price to earnings (P/E)
N/A
Price to book (P/B)
1.03
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$8.28M
Net income
-$13.2M
EBIT
-$13.2M
EBITDA
-$13.2M
Free cash flow
-$6.92M
Per share
Balance sheet
Liquidity
EPS
-$2.72
EPS diluted
-$2.72
Free cash flow per share
-$1.43
Book value per share
$0.64
Revenue per share
$0
TBVPS
$1.04
Total assets
$5.04M
Total liabilities
$975,858
Debt
$0
Equity
$4.07M
Working capital
$3.08M
Debt to equity
0
Current ratio
4.16
Quick ratio
3.84
Net debt/EBITDA
0.28
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-225.7%
Return on equity
-259.4%
Return on invested capital
-1,720.7%
Return on capital employed
-324.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADIL stock price
How has the Adial Pharmaceuticals stock price performed over time
Intraday
3.44%
1 week
-7.61%
1 month
-16.43%
1 year
-46.67%
YTD
-35.05%
QTD
3.44%
Financial performance
How have Adial Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$8.28M
Net income
-$13.2M
Gross margin
N/A
Net margin
N/A
Adial Pharmaceuticals's net income has plunged by 158% YoY
The operating income has declined by 20% year-on-year
Growth
What is Adial Pharmaceuticals's growth rate over time
Valuation
What is Adial Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 30% QoQ and by 24% YoY
The stock's price to book (P/B) is 77% less than its 5-year quarterly average of 4.4
ADIL's equity is down by 31% QoQ
Efficiency
How efficient is Adial Pharmaceuticals business performance
ADIL's return on assets has dropped by 68% year-on-year
ADIL's ROE is down by 42% YoY
The ROIC fell by 32% QoQ
Dividends
What is ADIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADIL.
Financial health
How did Adial Pharmaceuticals financials performed over time
Adial Pharmaceuticals's total liabilities has increased by 49% YoY and by 18% from the previous quarter
Adial Pharmaceuticals's quick ratio has decreased by 39% QoQ and by 11% YoY
Adial Pharmaceuticals's debt is 100% less than its equity
ADIL's equity is down by 31% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.